A Phase 2, open-label, multicenter study to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of inebilizumab in eligible pediatric participants 2 to \< 18 years of age with recently active neuromyelitis optica spectrum disorder (NMOSD) who are seropositive for autoantibodies against aquaporin-4 (AQP4-immunoglobulin \[Ig\]G).

Conditions

  • Neuromyelitis Optica Spectrum Disorder

Intervention

  • Inebilizumab

Principal Investigator

  • Aaen, Gregory

Sponsor

  • Horizon Therapeutics

*The source of data for this particular study is "ClinicalTrials.gov" and was last updated on 05/16/2024. Loma Linda University does not make any warranties, expressed or implied, with respect to such data, and, furthermore, assumes no liability for any party's use, or the results of such use of the data.

Request Information

Complete the form below to contact the study team and receive more information about this trial.